Syed Shabbir, MD
Neurology · Baltimore, MDNPI 1669868485
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 165 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by Biogen at 25.4% of the total. 2025 is the largest year on record at $996, more than ten times the $48 reported in 2020.
Across 165 payments — averaging $22.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$936
- AbbVie$754
- Eisai Inc.$253
- Genentech USA, Inc.$190
- Lilly USA, LLC$179
- Amgen$166
- plus $1K from 22 others
Across 3 payments — averaging $1876.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- TG Therapeutics, Inc.$6K
What the payments were for
- Food & beverage$3,684100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 42 | $936 |
| AbbVie | 38 | $754 |
| Eisai Inc. | 9 | $253 |
| Genentech USA, Inc. | 8 | $190 |
| Lilly USA, LLC | 9 | $179 |
| Amgen(2 entities) | 8 | $166 |
| UCB, Inc. | 4 | $145 |
| Novartis | 5 | $112 |
| Teva Pharmaceuticals USA, Inc. | 4 | $110 |
| Neurocrine Biosciences, Inc. | 4 | $95 |
| SK Life Science, Inc. | 3 | $87 |
| Banner Life Sciences, LLC | 3 | $76 |
| Johnson & Johnson | 3 | $65 |
| Argenx US, Inc. | 2 | $65 |
| Amneal Pharmaceuticals LLC | 3 | $56 |
| Tanabe Pharma America, Inc. | 2 | $51 |
| EMD Serono, Inc. | 2 | $49 |
| Sanofi | 2 | $44 |
| Livanova USA, Inc. | 2 | $43 |
| Acadia Pharmaceuticals Inc | 2 | $41 |
| Neurelis, Inc. | 2 | $30 |
| Bristol Myers Squibb | 2 | $29 |
| TG Therapeutics, Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $23 |
| Pfizer | 1 | $21 |
| Acorda Therapeutics, Inc | 1 | $16 |
| Avion Pharmaceuticals | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $8 |
How this compares
$3,684 in reported general payments places this provider in the 60th percentile of 442 neurology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VumerityDiroximel Fumarate | 17 | $227,000 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 12 | $97,599 |
| NuplazidPimavanserin Tartrate | 14 | $71,324 |
| Nurtec OdtRimegepant Sulfate | 27 | $34,542 |
| Emgality PenGalcanezumab-Gnlm | 38 | $32,520 |
| Aimovig AutoinjectorErenumab-Aooe | 15 | $16,093 |
| Levetiracetam | 254 | $12,182 |
| Memantine Hcl | 211 | $8,356 |
| Lacosamide | 20 | $5,695 |
| Clobazam | 23 | $5,587 |
| Lamotrigine OdtLamotrigine | 12 | $4,470 |
| Donepezil Hcl | 308 | $4,391 |
| Sumatriptan Succinate | 36 | $4,221 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 75 | $3,617 |
| Gabapentin | 133 | $3,260 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity | $936 | $227,00017 claims |
| Acadia Pharmaceuticals IncNuplazid | $41 | $71,32414 claims |
| PfizerNurtec Odt | $21 | $34,54227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 442 neurology providers in Maryland.
Other neurology in Baltimore
- Michael PolydefkisBaltimore$371K
- Shiv SaidhaBaltimore$298K
- Santiago Mazuera MesiaBaltimore$258K
- Thomas CrawfordBaltimore$215K
- Scott NewsomeBaltimore$203K
- Perry ForemanBaltimore$194K
- Samuel MillerBaltimore$179K
- Ted DawsonBaltimore$170K
- Charlene GamaldoBaltimore$131K
- Kathryn WagnerBaltimore$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.